<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00671502</url>
  </required_header>
  <id_info>
    <org_study_id>MP510</org_study_id>
    <nct_id>NCT00671502</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back</brief_title>
  <official_title>Randomized, Double-Blind, Double-Dummy Trial of Two Sustained Release Formulations of Carisoprodol Compared to Placebo in Subjects With Acute, Painful, Musculoskeletal Spasm of the Lower Back</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meda Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meda Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if two sustained released formulations of
      carisoprodol are more effective than placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methodology:

      This was a randomized, double-blind, double-dummy, placebo-controlled, parallel-group study
      in subjects 18-70 years of age with acute, painful, muscle spasm of the lower back. The study
      consisted of a baseline screening (Study Day 1), during which subjects were evaluated for
      inclusion/exclusion criteria, and a 7-day double-blind treatment period (Study Day 1 through
      Study Day 7). Subjects were randomly assigned to be dosed twice daily with one of the
      following double-blind treatments: sustained release(SR) carisoprodol 500-mg
      tablets,sustained release (SR) carisoprodol 700-mg tablets, or placebo.

      Subjects were evaluated in the clinic on Study Days 1, 3 and 7. Subjects who remained
      symptomatic on Study Day 7 were allowed to continue in the study for a 7-day, double-blind
      extension period at the discretion of the Investigator. Subjects were contacted by telephone
      for a safety follow-up 7 days after the last dose of study medication.

      A pharmacokinetic (PK) substudy was conducted at selected sites. These sites obtained blood
      samples for PK analysis at the end of the 7-day treatment period and the 14-day treatment
      period, if applicable.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subject Rating of Pain on a 100-point Visual Analog Scale (VAS)</measure>
    <time_frame>up to 14 days</time_frame>
    <description>the scale used was from 0 to 100 mm. 0 equaled no pain and 100 equaled maximum pain.participants measure their pain before treatment and during treatment at each visit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subject Functional Assessment Based on the Roland-Morris Disability Questionnaire (RMDQ)</measure>
    <time_frame>up to 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event Assessment</measure>
    <time_frame>up to 21 days</time_frame>
    <description>the number of adverse events reported during the course of the study as reported by the participants</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">840</enrollment>
  <condition>Lower Back Pain</condition>
  <arm_group>
    <arm_group_label>Carisoprodol 700mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tablet sustained release (SR)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carisoprodol 500mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sustained release(SR) tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carisoprodol SR</intervention_name>
    <description>700 mg twice daily</description>
    <arm_group_label>Carisoprodol 700mg</arm_group_label>
    <other_name>sustained release(SR)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carisoprodol SR</intervention_name>
    <description>500 mg twice daily</description>
    <arm_group_label>Carisoprodol 500mg</arm_group_label>
    <other_name>sustained release(SR) tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>no other name</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Onset of pain is within 3 days of first visit

          -  Subject rating of pain must be 40 mm or greater on visual analog scale( VAS)

          -  Ability to discontinue all analgesics, non steroidal anti inflammatory drug (NSAIDs),
             and other muscle relaxants

          -  Willingness to provide written informed consent

          -  Must be in generally good health

        Exclusion Criteria:

          -  Presence of sciatic pain

          -  History of clinically significant spine pathology such as herniated nucleas pulposis,
             spondylolisthesis, spinal stenosis

          -  Presence of underlying chronic back pain

          -  Neurological signs and symptoms such as numbness, tingling, foot drop, parethesia,
             unexplained constipation, urinary retention or urinary incontinence

          -  Myocardial infaction within one year of study

          -  Cancer not in remission or in remission less than one year

          -  HIV or other immunodeficiency syndromes

          -  History of osteoporosis or at high risk for vetebral fracture

          -  Underlying rheumatologic disease such as rheumatoid arthritis, ankylosing spondylitis,
             etc.

          -  Presence of active influenze or other viral syndromes

          -  Morbid obesity basal metabolic index(BMI &gt;39)

          -  Evidence of infection, such as low grade fever or neutrophilia

          -  Existence of any medical/surgical condition that could interfere with the evaluation
             of the study medication

          -  Known history of alcohol or drug abuse

          -  Injury involving high potential for litigation, including worker's compensation or
             automobile accidents

          -  Pregnancy or breast feeding

          -  Women of child-bearing potential not abstinent or not practicing a medically
             acceptable method of contraception

          -  Vertebral body or spinous process, percussive tenderness on physical exam

          -  Any abnormalities in the following tests of both lower extremities: ankle dorsiflexion
             strength, great toe dorsiflexion strength, absent or hypereflexic Achilles or patellar
             tendor reflexes, abnormal sensory exam in the medial, dorsal or lateral aspect of the
             foot and positive straight leg raise test

          -  Urgent medical conditions on comprehensive exam that might indicate a more serious
             condition should be treated urgently
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lewis M. Fredane, MD</last_name>
    <role>Study Director</role>
    <affiliation>Meda Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MedSearch, LLC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genesis Clinical Research Corporation</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vaughn H. Mancha, Jr., PC Family Practice</name>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <zip>36117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anasazi Internal Medicine PC</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heritage Physician Group</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OrthoArkansas</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Practice Clinic</name>
      <address>
        <city>North Little Rock</city>
        <state>Arkansas</state>
        <zip>72114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quality of Life Medical Center, LLC</name>
      <address>
        <city>Hawaiian Gardens</city>
        <state>California</state>
        <zip>90716</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trinity Health and Wellness</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Diego Sports Medicine &amp; Family Health Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quality Care Medical Center, Inc.</name>
      <address>
        <city>Vista</city>
        <state>California</state>
        <zip>92084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anthony Roselli, MD</name>
      <address>
        <city>Avon</city>
        <state>Connecticut</state>
        <zip>06001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of South Florida</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Integrated Medical, PL dba Florida Medical Research Institute</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida Clinical Research Center</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FPA Clinical Research</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genesis Research International</name>
      <address>
        <city>Longwood</city>
        <state>Florida</state>
        <zip>32779</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Well Pharma Medical Research Corporation</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Research Associates, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33156</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tukoi Clinical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renstar Medical Research</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Research, Inc.</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunrise Medical Research #501</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Florida Clinical Research Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Beach Research Center</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perimeter Institute for Clinical Research, Inc.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30338</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunset Medical Research</name>
      <address>
        <city>Sunset</city>
        <state>Louisiana</state>
        <zip>70584</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Pharmacology Study Group</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Pines Health Center</name>
      <address>
        <city>Buckley</city>
        <state>Michigan</state>
        <zip>49620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KMED Research</name>
      <address>
        <city>Clair Shores</city>
        <state>Michigan</state>
        <zip>48081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harris &amp; Associates, P.C.</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Medical Center</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westside Family Medical Center, P.C.</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City University of Medicine and BioSciences Dybedal Building</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Clinical Research</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Jersey Medical Associations, PA</name>
      <address>
        <city>Blackwood</city>
        <state>New Jersey</state>
        <zip>08012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Care Center of Family Practice &amp; Pediatrics of Hamilton</name>
      <address>
        <city>Hamilton</city>
        <state>New Jersey</state>
        <zip>08610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Partners in Primary Care</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albuquerque Clinical Trials, Inc.</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metrolina Medical Research</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Source Inc.</name>
      <address>
        <city>Perrysburg</city>
        <state>Ohio</state>
        <zip>43551</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Practice Center of Wadsworth, Inc.</name>
      <address>
        <city>Wadsworth</city>
        <state>Ohio</state>
        <zip>44281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integrated Medical Research</name>
      <address>
        <city>Ashland</city>
        <state>Oregon</state>
        <zip>97520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Williamette Valley Clinical Studies</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>91404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fanno Creek Clinic, LLC</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Best Clinical Research - PA</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcuri Clinical Research</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19142</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Partners in Clinical Research</name>
      <address>
        <city>Cumberland</city>
        <state>Rhode Island</state>
        <zip>02864</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omega Medical Research</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert S. Eagerton Jr., MD Family Practice</name>
      <address>
        <city>Manning</city>
        <state>South Carolina</state>
        <zip>29102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holston Medical Group, P.C.</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ACRC Trials</name>
      <address>
        <city>Addison</city>
        <state>Texas</state>
        <zip>75001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arlington Family Health Pavilion</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central TX Clinical Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid-Cities Family Care</name>
      <address>
        <city>Bedford</city>
        <state>Texas</state>
        <zip>76021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evergreen Clinical Research, LLC</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deer Park Family Clinic, P.A.</name>
      <address>
        <city>Deer Park</city>
        <state>Texas</state>
        <zip>77536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prime Care Medical Group</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Houston Clinical Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Hills Family Practice</name>
      <address>
        <city>North Richland Hills</city>
        <state>Texas</state>
        <zip>76180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Texas Family Medicine</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Research Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unlimited Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InVisions Consultants, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oakwell Clinical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Research of Hampton Roads, Inc.</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research Initiatives</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liberty Research Center</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2008</study_first_submitted>
  <study_first_submitted_qc>May 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2008</study_first_posted>
  <results_first_submitted>June 28, 2011</results_first_submitted>
  <results_first_submitted_qc>October 4, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 9, 2011</results_first_posted>
  <last_update_submitted>October 4, 2011</last_update_submitted>
  <last_update_submitted_qc>October 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carisoprodol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Carisoprodol 700mg</title>
          <description>tablet experimental formulation</description>
        </group>
        <group group_id="P2">
          <title>Carisoprodol 500mg Tablet</title>
          <description>tablet experimental formulation</description>
        </group>
        <group group_id="P3">
          <title>Placebo Tablet</title>
          <description>tablet placebo no experimental formulation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="281"/>
                <participants group_id="P2" count="280"/>
                <participants group_id="P3" count="279"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="242"/>
                <participants group_id="P2" count="241"/>
                <participants group_id="P3" count="252"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="27"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Carisoprodol 700mg</title>
          <description>tablet experimental formulation</description>
        </group>
        <group group_id="B2">
          <title>Carisoprodol 500mg Tablet</title>
          <description>tablet experimental formulation</description>
        </group>
        <group group_id="B3">
          <title>Placebo Tablet</title>
          <description>tablet placebo no experimental formulation</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="281"/>
            <count group_id="B2" value="280"/>
            <count group_id="B3" value="279"/>
            <count group_id="B4" value="840"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="278"/>
                    <measurement group_id="B2" value="278"/>
                    <measurement group_id="B3" value="275"/>
                    <measurement group_id="B4" value="831"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.3" spread="13.05"/>
                    <measurement group_id="B2" value="41.4" spread="12.6"/>
                    <measurement group_id="B3" value="40.9" spread="12.72"/>
                    <measurement group_id="B4" value="40.9" spread="12.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                    <measurement group_id="B2" value="144"/>
                    <measurement group_id="B3" value="136"/>
                    <measurement group_id="B4" value="413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="148"/>
                    <measurement group_id="B2" value="136"/>
                    <measurement group_id="B3" value="143"/>
                    <measurement group_id="B4" value="427"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="281"/>
                    <measurement group_id="B2" value="280"/>
                    <measurement group_id="B3" value="279"/>
                    <measurement group_id="B4" value="840"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subject Rating of Pain on a 100-point Visual Analog Scale (VAS)</title>
        <description>the scale used was from 0 to 100 mm. 0 equaled no pain and 100 equaled maximum pain.participants measure their pain before treatment and during treatment at each visit</description>
        <time_frame>up to 14 days</time_frame>
        <population>efficacy analyses based on ITT population. LOCF used to impute missing data. To detect a 14% difference between the carisoprodol and placebo treated subjects, 196 ITTsubjects per group (alpha level 0.025,power 80%).Assuming 15% dropout rate, 226 subjects per group were needed.A total of678 subjects were required to achieve 584 ITT subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Carisoprodol 500mg Tablets</title>
            <description>carisoprodol 500mg tablets treatment arm</description>
          </group>
          <group group_id="O2">
            <title>Carisoprodol 700mg Tablets</title>
            <description>carisoprodol 700mg tablets treatment arm</description>
          </group>
          <group group_id="O3">
            <title>Placebo Tablets</title>
            <description>placebo tablets treatment arm</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Rating of Pain on a 100-point Visual Analog Scale (VAS)</title>
          <description>the scale used was from 0 to 100 mm. 0 equaled no pain and 100 equaled maximum pain.participants measure their pain before treatment and during treatment at each visit</description>
          <population>efficacy analyses based on ITT population. LOCF used to impute missing data. To detect a 14% difference between the carisoprodol and placebo treated subjects, 196 ITTsubjects per group (alpha level 0.025,power 80%).Assuming 15% dropout rate, 226 subjects per group were needed.A total of678 subjects were required to achieve 584 ITT subjects.</population>
          <units>mm</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="281"/>
                <count group_id="O3" value="279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.5" lower_limit="-21" upper_limit="83"/>
                    <measurement group_id="O2" value="28" lower_limit="-19" upper_limit="89"/>
                    <measurement group_id="O3" value="28.6" lower_limit="-36" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Functional Assessment Based on the Roland-Morris Disability Questionnaire (RMDQ)</title>
        <time_frame>up to 14 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Event Assessment</title>
        <description>the number of adverse events reported during the course of the study as reported by the participants</description>
        <time_frame>up to 21 days</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 21 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Carisoprodol 700mg</title>
          <description>tablet experimental formulation</description>
        </group>
        <group group_id="E2">
          <title>Carisoprodol 500mg Tablet</title>
          <description>tablet experimental formulation</description>
        </group>
        <group group_id="E3">
          <title>Placebo Tablet</title>
          <description>tablet placebo no experimental formulation</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MeDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>transient ischemic attack</sub_title>
                <description>occurred after discontinuation of drug therefore not considered treatment emergent</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="275"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.7</frequency_threshold>
        <default_vocab>MeDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="280"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="275"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="278"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="280"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="275"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="278"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="280"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="275"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="278"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="280"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="275"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>somnolence</sub_title>
                <counts group_id="E1" events="44" subjects_affected="44" subjects_at_risk="44"/>
                <counts group_id="E2" events="36" subjects_affected="36" subjects_at_risk="280"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="275"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="278"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="280"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="275"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Ginsberg, MD Sr Medical Director</name_or_title>
      <organization>Meda Pharma US</organization>
      <phone>732 564 2364</phone>
      <email>david.ginsberg@meda.us</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

